Accepted for Publication: October 5, 2021.
Published Online: January 13, 2022. doi:10.1001/jamaoncol.2021.6597
Corresponding Author: Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (sara_tolaney@dfci.harvard.edu).
Author Contributions: Dr Tarantino had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Tarantino, Curigliano, Parsons, Krop, Winer, Tolaney.
Acquisition, analysis, or interpretation of data: Tarantino, Curigliano, Lin, Mittendorf, Waks, Tolaney.
Drafting of the manuscript: Tarantino, Curigliano, Mittendorf, Tolaney.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, or material support: Tarantino, Curigliano, Tolaney.
Supervision: Tarantino, Curigliano, Parsons, Krop, Tolaney.
Conflict of Interest Disclosures: Dr Tarantino has served as an adviser/consultant to AstraZeneca and is supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship. Dr Curigliano received honoraria for speaker, consultancy, or advisory roles from Roche, Pfizer, Novartis, Seattle Genetics, Lilly, Ellipses Pharma, Foundation Medicine, Daiichi Sankyo, and Samsung. Dr Parsons is a paid consultant for Foundation Medicine. Dr Lin reports research support (to institution) from Genentech, Merck, Pfizer, and Seattle Genetics; consultant/advisory board: Puma, Seattle Genetics, Daiichi Sankyo, AstraZeneca, Denali Therapeutics, California Institute for Regenerative Medicine, and Prelude Therapeutics. Dr Krop reports research support (to institution) from Genentech/Roche and Pfizer, has received fees from Novartis and Merck for Data Monitoring Board participation, received honoraria from Celltrion, and has received consulting fees from Bristol Myers Squibb, Daiichi/Sankyo, Macrogenics, Context Therapeutics, Taiho Oncology, Genentech/Roche, Seattle Genetics, and AstraZeneca. Dr Mittendorf has received research support from GlaxoSmithKline; honoraria from Physician Education Resource; compensation for serving on advisory boards for AstraZeneca, Exact Sciences, Merck, Peregrine Pharmaceuticals, Roche/Genentech, Sellas Lifesciences, and TapImmune; institutional support from AstraZeneca, EMD Serono, Galena Biopharma, and Roche/Genentech; and has served as an uncompensated steering committee member for Bristol Myers Squibb, Lilly and Roche/Genentech. Dr Waks receives institutional research funding from Genentech/Roche. Dr Winer is a scientific advisory board member for Leap, and reports consultancy fees from Garrick Therapeutics, G1 Therapeutics, Roche Genentech, Genomic Health, GlaxoSmithKline, Jounce, Lilly, Novartis, Seattle Genetics, and Syros, outside the submitted work. Dr Tolaney receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Exelixis, Bristol Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an adviser/consultant to AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Bristol Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Puma, Silverback Therapeutics, G1 Therapeutics, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, Ellipsis, Infinity, 4D Pharma, Samsung Bioepsis, Inc, Chugai Pharmaceuticals, BeyondSpring Pharmaceuticals, OncXerna, OncoSec Medical Incorporated, Certara, Mersana Therapeutics, CytomX, Seattle Genetics.
Additional Contributions: We thank Kate Bifolck, BA, for her editorial and submission assistance (full-time employee of Dana-Farber Cancer Institute).
3.Stadtmauer
EA , O’Neill
A , Goldstein
LJ ,
et al; Philadelphia Bone Marrow Transplant Group. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
N Engl J Med. 2000;342(15):1069-1076. doi:
10.1056/NEJM200004133421501PubMedGoogle ScholarCrossref 5.Swain
SM , Miles
D , Kim
S-B ,
et al; CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Lancet Oncol. 2020;21(4):519-530. doi:
10.1016/S1470-2045(19)30863-0PubMedGoogle ScholarCrossref 7.Miles
D , Ciruelos
E , Schneeweiss
A ,
et al; PERUSE investigators. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Ann Oncol. 2021;32(10):1245-1255. doi:
10.1016/j.annonc.2021.06.024PubMedGoogle ScholarCrossref 14.Harano
K , Lei
X , Gonzalez-Angulo
AM ,
et al. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.
Breast Cancer Res Treat. 2016;159(2):367-374. doi:
10.1007/s10549-016-3933-6PubMedGoogle ScholarCrossref 15.den Brok
WD , Speers
CH , Gondara
L , Baxter
E , Tyldesley
SK , Lohrisch
CA . Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
Breast Cancer Res Treat. 2017;161(3):549-556. doi:
10.1007/s10549-016-4080-9PubMedGoogle ScholarCrossref 18.Hopkins
AM , Rowland
A , McKinnon
RA , Sorich
MJ . Predictors of long-term disease control and survival for HER2-positive advanced breast cancer patients treated with pertuzumab, trastuzumab, and docetaxel.
Front Oncol. 2019;9:789. doi:
10.3389/fonc.2019.00789PubMedGoogle ScholarCrossref 21.Baselga
J , Lewis Phillips
GD , Verma
S ,
et al. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
Clin Cancer Res. 2016;22(15):3755-3763. doi:
10.1158/1078-0432.CCR-15-2499PubMedGoogle ScholarCrossref 22.Kim
S-B , Wildiers
H , Krop
IE ,
et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician’s choice in previously treated HER2-positive advanced breast cancer.
Int J Cancer. 2016;139(10):2336-2342. doi:
10.1002/ijc.30276PubMedGoogle ScholarCrossref 23.Burris
HA
III , Rugo
HS , Vukelja
SJ ,
et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
J Clin Oncol. 2011;29(4):398-405. doi:
10.1200/JCO.2010.29.5865PubMedGoogle ScholarCrossref 24.Esteva
FJ , Guo
H , Zhang
S ,
et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Am J Pathol. 2010;177(4):1647-1656. doi:
10.2353/ajpath.2010.090885PubMedGoogle ScholarCrossref 25.Luen
SJ , Salgado
R , Fox
S ,
et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Lancet Oncol. 2017;18(1):52-62. doi:
10.1016/S1470-2045(16)30631-3PubMedGoogle ScholarCrossref 29.Cortes
J , Kim
S-B , Chung
W-P ,
et al. LBA1—Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study.
Ann Oncol. 2021;32(suppl_5):S1283-S1346.
Google Scholar 31.Lin
NU , Borges
V , Anders
C ,
et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial.
J Clin Oncol. 2020:JCO.20.00775. doi:
10.1200/JCO.20.00775Google ScholarCrossref 32.Stemmler
H-J , Schmitt
M , Willems
A , Bernhard
H , Harbeck
N , Heinemann
V . Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
Anticancer Drugs. 2007;18(1):23-28. doi:
10.1097/01.cad.0000236313.50833.eePubMedGoogle ScholarCrossref 33.Swain
SM , Baselga
J , Miles
D ,
et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
Ann Oncol. 2014;25(6):1116-1121. doi:
10.1093/annonc/mdu133PubMedGoogle ScholarCrossref 34.Pestalozzi
BC , Holmes
E , de Azambuja
E ,
et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
Lancet Oncol. 2013;14(3):244-248. doi:
10.1016/S1470-2045(13)70017-2PubMedGoogle ScholarCrossref 36.Rugo
HS , Im
SA , Cardoso
F ,
et al; SOPHIA Study Group. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial.
JAMA Oncol. 2021;7(4):573-584. doi:
10.1001/jamaoncol.2020.7932PubMedGoogle ScholarCrossref 38.Salgado
R , Denkert
C , Campbell
C ,
et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial.
JAMA Oncol. 2015;1(4):448-454. doi:
10.1001/jamaoncol.2015.0830PubMedGoogle ScholarCrossref 39.Nuciforo
P , Prat
A , Llombart
A ,
et al Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial.
Ann Oncol. 2017;28:v46. doi:
10.1093/annonc/mdx362.006Google ScholarCrossref 45.Reck
M , Rodríguez-Abreu
D , Robinson
AG ,
et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%.
J Clin Oncol. 2021;39(21):2339-2349. doi:
10.1200/jco.21.00174Google ScholarCrossref 46.Albiges
L , Tannir
NM , Burotto
M ,
et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
ESMO Open. 2020;5(6):e001079. doi:
10.1136/esmoopen-2020-001079PubMedGoogle ScholarCrossref 47.Nghiem
P , Bhatia
S , Brohl
AS ,
et al. Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up.
J Clin Oncol. 2021;39(suppl_15):9517-9517. doi:
10.1200/JCO.2021.39.15_suppl.9517Google ScholarCrossref 51.Emens
LA , Esteva
FJ , Beresford
M ,
et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Lancet Oncol. 2020;21(10):1283-1295. doi:
10.1016/S1470-2045(20)30465-4PubMedGoogle ScholarCrossref 52.Loi
S , Giobbie-Hurder
A , Gombos
A ,
et al; International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Lancet Oncol. 2019;20(3):371-382. doi:
10.1016/S1470-2045(18)30812-XPubMedGoogle ScholarCrossref 53.Huober
J , Barrios
CH , Niikura
N ,
et al VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC).
Ann Oncol. 2021;32(8):1061-1062. doi:
10.1016/j.annonc.2021.05.800Google ScholarCrossref 56.Khan
SA , Zhao
F , Solin
LJ ,
et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
J Clin Oncol. 2020;38(suppl_18):LBA2-LBA2. doi:
10.1200/JCO.2020.38.18_suppl.LBA2Google ScholarCrossref 59.Janni
WJ , Yab
TC , Hayes
DF ,
et al. Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC)—a global pooled analysis with individual patient data. In:
General Session Abstracts. American Association for Cancer Research. 2021:GS4-08-GS4-08. doi:
10.1158/1538-7445.SABCS20-GS4-08